How to Read Peptide Research: Understanding Study Design, Animal vs Human Dosing, and Effect Sizes

Much of what circulates online about peptides originates from published research, but the quality and applicability of that research varies enormously. Understanding how to critically evaluate a peptide study is essential for anyone reviewing the literature, whether as a researcher, clinician, or informed reader. This guide covers the key concepts: study design hierarchy, the complexities of translating animal doses to humans, and how to interpret effect sizes in context.

The Peptide Register catalogues peptide profiles with structured evidence summaries, but every reader benefits from knowing how to assess the underlying studies themselves. The sections below offer a framework for doing exactly that.

Study Design Hierarchy: Why Not All Evidence Is Equal

Research studies exist on a well-established hierarchy of evidence. At the base sit in vitro studies (cell cultures and tissue models), which can demonstrate a mechanism of action but say little about what happens in a living organism. Animal studies (in vivo) sit above these; they offer physiological context but involve species whose metabolism, receptor density, and pharmacokinetics often differ substantially from humans.

Above animal models come human trials, which themselves vary in rigour. Observational studies and case reports are exploratory. Randomised controlled trials (RCTs) provide stronger causal evidence, particularly when double-blinded and placebo-controlled. Systematic reviews and meta-analyses, which pool data from multiple RCTs, represent the highest tier of evidence.

Most published peptide research consists of animal studies and small, early-phase human trials. Many peptide compounds discussed in research literature have no completed Phase III human RCTs. When evaluating any peptide study, the first question should always be: what type of study is this, and where does it sit on the evidence hierarchy?

For context on how study limitations affect specific peptides, the Peptide Register's overview of BPC-157 research illustrates how a compound can have extensive animal data but limited human clinical trial evidence.

Translating Doses From Animal Models to Humans

One of the most common errors in interpreting peptide research is assuming that a dose used in a rodent study can be directly applied to humans. It cannot. Allometric scaling, which accounts for differences in body surface area and metabolic rate between species, is the standard method for estimating human equivalent doses (HEDs).

The FDA guidance document for estimating safe starting doses in clinical trials uses a body surface area conversion factor. A commonly cited conversion factor from mouse to human is approximately 0.081, meaning a 10 mg/kg dose in a mouse corresponds to roughly 0.81 mg/kg in a human. For rats, the conversion factor is approximately 0.162. These are approximations, not precise translations; they do not account for species-specific differences in receptor binding, peptide half-life, or metabolic clearance.

Allometric dose conversion from mouse to human uses a factor of approximately 0.081, based on FDA body surface area scaling guidance. This means a dose effective in mice may appear far less feasible or relevant at human-equivalent levels. Some peptide studies in rodents use doses that, when scaled, would be impractical or potentially unsafe in humans. Reporting dose in mg/kg without species context is a significant red flag in any summary of peptide research. For more on how delivery method compounds this complexity, see the Peptide Register's comparison of peptide bioavailability across delivery routes.

Effect Sizes, Statistical Significance, and Clinical Relevance

A study may report statistically significant results, meaning the observed effect is unlikely to be due to chance alone (typically p < 0.05). However, statistical significance does not automatically mean clinical relevance. A peptide might produce a statistically significant change in a biomarker, but if the magnitude of that change is small, its practical meaning may be negligible.

Effect size measures such as Cohen's d or standardised mean difference quantify how large an observed effect actually is. A Cohen's d of 0.2 is generally considered small, 0.5 medium, and 0.8 or above large. Many peptide studies report results without effect size calculations, making it difficult to assess practical significance.

Small sample sizes, common in early peptide research, inflate the risk of both false positives and imprecise effect estimates. A study with 10 participants per group that reports a significant finding should be interpreted with far more caution than one with 200 per group. Small sample sizes in early-phase peptide trials increase the risk of false positives and imprecise effect size estimates. Replication, the confirmation of findings by independent research groups, remains one of the most important markers of reliable evidence. Many peptide findings have not been independently replicated.

Practical Checklist for Evaluating Peptide Studies

When reviewing any peptide study, consider the following questions. Was the study conducted in animals or humans? If in humans, was it randomised, blinded, and placebo-controlled? What was the sample size, and is it large enough to draw meaningful conclusions? Has the finding been replicated by independent groups? Is the reported dose applicable to humans after allometric scaling? Does the study report effect sizes, or only p-values? Are the authors affiliated with entities that could present conflicts of interest?

Most published peptide research lacks completed Phase III human randomised controlled trials. This does not mean the research is without value, but it does mean that claims of definitive benefit are premature. The peptide safety literature further underscores why caution is warranted when extrapolating from limited evidence. The Peptide Register's glossary defines many of the technical terms used throughout study literature, and its peptide database notes the evidence tier for each profiled compound.